CoChat

Glucagon‐like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta‐analysis

Liu, Fu‐peng, Dong, Jian‐jun, Yang, Qing, Xue, Xian‐zhong, Ren, Zhong‐fa, Gan, Yi‐zhang, Liao, Lin · 2015 · Journal of Diabetes
Cited by 20

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Background: The aim of the present study was to compare the reported efficacy and safety of glucagon‐like peptide‐l receptor agonist (GLP‐1RA) and insulin glargine (IGlar) for poorly controlled type 2 diabetes. Methods: Medline, EMBASE, C ochrane L ibrary, and clinicaltrials.gov were carried out. References and cited papers of relevant articles were also checked. Results: Seven trials met the inclusion criteria. GLP‐1RA showed equivalent or superior efficacy to IGlar for reducing hemoglobin A 1c (HbA1c), with a greater proportion of patients achieving HbAlc<7%. GLP‐1RA also favored decreased body weight, total cholesterol (TC), low‐density lipoprotein (LDL), and systolic blood pressure (SBP). Serious adverse events were uncommon and not significantly different. More patients taking GLP‐1RA experienced gastrointestinal complications: nausea, diarrhea, and vomiting. Severe hypoglycemia events were rare, and minor hypoglycemia was less common for GLP‐1RA. Conclusions: GLP‐1RA showed greater efficacy compared to IGlar for type 2 diabetes, and it may also prove beneficial for other diabetes‐associated characteristics, including obesity, hypertension, and hyperlipidemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/1753-0407.12200

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 20

Metadata

Authors
Liu, F., Dong, J., Yang, Q., Xue, X., Ren, Z., Gan, Y., & Liao, L.
Venue
Journal of Diabetes
Publisher
Wiley
Published
2014-09-10
Volume
7
Issue
3
Pages
322-328
ISSN
  • 1753-0393 (ISSN-L)
  • 1753-0407
OpenAlex
W2158530272
Cited by
20
References
10
FWCI
0.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon‐like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/1753-0407.12200
The paper
Liu, F., Dong, J., Yang, Q., Xue, X., Ren, Z., Gan, Y., & Liao, L. (2015). Glucagon‐like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta‐analysis. Journal of Diabetes. https://doi.org/10.1111/1753-0407.12200

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.